Scientists track patients for years after experimental cancer treatment
NCT ID NCT05017662
Summary
This study monitored 20 patients who had previously received an experimental treatment called 177Lu-satoreotide tetraxetan for neuroendocrine tumors. Researchers tracked their long-term health to check for any delayed side effects or new cancers that might be related to the treatment. The study involved regular check-ups and blood tests specifically for safety monitoring purposes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Hôtel Dieu de Nantes
Nantes, 44093 Cedex 1, France
-
Medical University of Vienna
Vienna, 1090, Austria
-
Peter Maccallum Cancer Center
Melbourne, 3002, Australia
-
Ramsay Hollywood Private Hospital
Perth, 6009, Australia
-
Royal Free Hospital London
London, NW3 2QG, United Kingdom
-
University Hospital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.